Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. raised its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 54.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 112,841 shares of the company's stock after buying an additional 40,001 shares during the period. D. E. Shaw & Co. Inc. owned about 0.15% of Nurix Therapeutics worth $2,126,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in NRIX. FMR LLC raised its stake in shares of Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after purchasing an additional 10,047,329 shares during the period. RA Capital Management L.P. purchased a new stake in shares of Nurix Therapeutics during the fourth quarter valued at approximately $25,120,000. Boxer Capital Management LLC purchased a new stake in shares of Nurix Therapeutics during the fourth quarter valued at approximately $10,608,000. Vanguard Group Inc. raised its stake in shares of Nurix Therapeutics by 8.3% during the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after purchasing an additional 333,452 shares during the period. Finally, Norges Bank purchased a new stake in shares of Nurix Therapeutics during the fourth quarter valued at approximately $6,006,000.

Insider Activity

In other news, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at approximately $488,660.76. The trade was a 14.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider now directly owns 61,516 shares of the company's stock, valued at approximately $707,434. This trade represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. JPMorgan Chase & Co. dropped their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Leerink Partners assumed coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They set a "market perform" rating and a $16.00 price objective on the stock. Wall Street Zen lowered shares of Nurix Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday. Finally, HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Trading Down 2.7%

Nurix Therapeutics stock traded down $0.27 during mid-day trading on Friday, reaching $9.72. The company's stock had a trading volume of 401,505 shares, compared to its average volume of 871,857. The firm has a market cap of $741.01 million, a price-to-earnings ratio of -3.36 and a beta of 2.23. The business has a 50 day moving average price of $10.75 and a 200-day moving average price of $16.50. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same quarter in the previous year, the company posted ($0.76) earnings per share. On average, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.